Telomerase expression is the hallmark of tumor cells in which this ribonucleoprotein complex preserves chromosome integrity by maintaining telomere length and thereby prevents cell death. However, recent data support a role of the combination of p53 and telomerase inactivation in initiating genetic instability that promotes malignant transformation. Through its pleiotropic effects on infected T-cell metabolism, the human T-cell leukemia virus type 1 (HTLV-1) oncoprotein Tax plays a central role in leukemogenesis. Here, we show that Tax inhibits human telomerase reverse transcriptase (hTERT) transcription, which is the rate-limiting factor of telomerase activity. This inhibitory effect, that occurs in competition with c-Myc through a canonical c-Myc binding site within the hTERT promoter, results in a decreased telomerase activity of Tax-expressing cells. This is the first demonstration of hTERT inhibition by an oncogene. Tax, which is only expressed in preleukemic cells, triggers infected T-cell cycle and keeps these cells cycling while inactivating p53. We propose that, in combination with these effects, hTERT repression by Tax at an early phase of carcinogenesis might contribute to the massive ploidy changes associated with the development of HTLV-1-associated malignancies.
Introduction
By generating numerous gains and losses of chromosome segments, chromosomal rearrangement mechanisms are intimately linked to cancer development (Nishizaki et al., 1997; Buerger et al., 1999) . In fact, the generation of potentially oncogenic chromosomal abnormalities might result from the progressive telomere attrition that accompanies cell divisions . Indeed, telomere dysfunction generates chromosome end-to-end fusions, thus forming dicentric and multicentric chromosomes that can break during mitosis de Lange and Jacks, 1999) . These acquired genetic rearrangements may activate DNA damage checkpoints, leading to cellular senescence or cell death (Counter et al., 1992) . Accordingly, the loss of a DNA damage checkpoint, such as p53 inactivation, allows both extended cell survival and continued telomere shortening (Blasco et al., 1997; Rudolph et al., 2001) . This promotes accumulation of increased chromosomal aberrations and aneuploidy, thereby establishing a procancer genotype that subsequent telomerase reactivation can stabilize, leading to malignant transformation (Blasco et al., 1997; Rudolph et al., 2001) . The implication of telomere dysfunction in early carcinogenesis has been clearly documented in vitro and in animal models in vivo (Blasco et al., 1997; Rudolph et al., 2001) , suggesting that telomerase inactivation could play a role in tumor initiation. Despite these observations, no clear evidence of telomerase inactivation in early human carcinogenesis, or of its mechanism, has been given to date. On the contrary, all the factors that negatively interfere with human telomerase, such as Mad (Oh et al., 2000) , p53 , p16 , p21 (Kusumoto et al., 1999) , E2F-1 (Crowe et al., 2001 ) and the nononcogenic E2 product from papillomavirus (Lee et al., 2002) , are known to promote cellular differentiation, cell-cycle arrest, tumor suppression and/or apoptosis.
The human T-cell leukemia virus type 1 (HTLV-1) retrovirus infects and activates T cells (Hollsberg, 1999) . After a prolonged period of latency during which infected cells express Tax, proliferate persistently and harbor a high degree of genetic instability (Mortreux et al., 2001) , 3-5% of infected individuals develop adult T-cell leukemia/lymphoma (ATLL). In contrast to many other leukemias or lymphomas, ATLL cells display numerous and nonrecurrent cytogenetic abnormalities that bear striking similarities to those resulting from telomere dysfunction observed in solid tumors, that is, unbalanced translocations, deletions, duplications or triplications (Itoyama et al., 2001) . Tax possesses many oncogenic properties (Yoshida, 2001) . It induces the expression of numerous genes involved in the differentiation and the proliferation of T cells (Fujii et al., 1991; Inoue et al., 1986) and inhibits transforming growth factor b signalling by blocking the association of Smad proteins with Smad-binding element (Lee et al., 2002) . Furthermore, through the functional inactivation of P16INKA4 (Suzuki et al., 1996) and the activation of cyclin D2 (Santiago et al., 1999) and cyclin D3 (Neuveut et al., 1998) , Tax intervenes directly in the pathway controlling T-cell proliferation.
In addition to its positive effect on cell cycling, Tax protein negatively interferes with some DNA repair functions of the host cells. Indeed, Tax inactivates in trans the promoter of human b polymerase (Jeang et al., 1990) and disrupts other prominent cellular DNA repair pathways (Kao and Marriott, 1999; Philpott and Buehring, 1999) . Via p53, Tax influences the transition from G1 to S phase and impairs the DNA-damage sentinel at this junction (PiseMasison et al., 1998) . Furthermore, Tax functionally inhibits the human mitotic checkpoint protein MAD1 (Jin et al., 1998) . These functional characteristics of Tax may explain its mutagenic effect on cellular chromosomal DNA, as recently evidenced in vitro and in vivo (Miyake et al., 1999; Mortreux et al., 2001) . However, because it is expressed in preleukemic cells but silent in ATLL cells (Furukawa et al., 1995; Hanon et al., 2000) , Tax only plays a role in the initiation of leukemogenesis (Furukawa et al., 1995; Hanon et al., 2000) .
The human telomerase reverse transcriptase (hTERT) promoter contains several transcription-factor binding sites, including basic helix-loop-helix (bHLH) binding sites that mediate hTERT transcriptional activation by c-Myc (Horikawa et al., 1999; Wu et al., 1999) . Such consensus sequences (CANNTG), referred to as E-boxes, are also implicated in the Tax-associated transcriptional inhibition of several cellular genes (Riou et al., 2000) including lck (Lemasson et al., 1997 ), p53 (Pise-Masison et al., 2000 and human beta-polymerase (Jeang et al., 1990) . Collectively, these data permitted to hypothesize that Tax might repress hTERT transcription, resulting in telomerase inactivation in Tax-expressing cells.
Results

Decreased telomerase activity in HTLV-1 cell lines expressing Tax
Telomerase activity was first measured by a semiquantitative telomeric repeat amplification protocol assay (TRAP) in HTLV-1 infected and -uninfected cell lines. hTERT activity strongly varied between cell lines (Figure 1a) . The mean relative hTERT activity (arbitrary units) of HTLV-1-positive and negative cell lines were 9.5 and 15.75, respectively (P ¼ 0.028). Five of the eight HTLV-1-positive cell lines expressed Tax (Figure 1a) , as evidenced by Western blotting (not shown). The mean relative telomerase activity in Tax positive and -negative cell lines were 5.8 and 15.71, respectively (Po10
À4
). These strong differences suggested that Tax expression was associated with a decrease of telomerase activity.
Tax downregulates the hTERT promoter in HeLa and Jurkat cells, thereby decreasing hTERT expression and activity
The above results, together with the presence of E-boxes within the hTERT promoter, prompted us to test whether Tax could repress hTERT transcription. Accordingly, we investigated the effect of Tax on hTERT expression by performing transient cotransfection assays with HeLa and Jurkat cells using the wild-type hTERT promoter-luciferase reporter plasmid TERTLuc800 and a Tax expression vector. TERTLuc800 carries the 800 bp promoter fragment from hTERT including the regions required for basal hTERT transcription (Horikawa et al., 1999) . This construct includes two canonical c-Myc-responsive E-boxes (CACGTG) (Horikawa et al., 1999; Wu et al., 1999) through which c-Myc efficiently activates hTERT transcription (Wu et al., 1999) . TERTLuc800 was transiently transfected with either empty vector (pCMV) or increasing amounts of a Tax expression vector (pCMV-Tax) (Riou et al., 2000) , as detailed in the Methods section. pCMV-Tax inhibited TERTLuc800 expression in a concentration-dependent manner ( Figure 2a ): for the lowest (10 ng) and highest (150 ng) amounts of transfected pCMV-Tax, 1.20-and a two-fold repressions of hTERT transcriptional activity were observed, respectively ( Figure 2a) . A Tax-associated hTERT repression was also observed with Jurkat lymphoid cell line ( Figure 2b ). This correlated with a decrease in cellular hTERT expression, as evidenced by RT-PCR amplification of the endogenous hTERT mRNA (Figure 2c ). In order to validate these results at the functional level, we investigated the consequence of Tax expression on the capacity of endogenous telomerase to catalyze telomere elongation. A quantitative TRAP assay was performed with cellular extracts from pCMV and pCMV-Tax transfected cells. Transfection of HeLa cells with Tax inhibited telomerase activity in a dose-dependent manner ( Figure 2d ): for the lowest (10 ng) and highest (150 ng) amounts of transfected pCMV-Tax, 1.70-and four-fold repressions of telomerase activity were observed, respectively ( Figure 2d ). This demonstrated that Tax-associated hTERT transrepression is associated with a loss of telomerase activity.
Tax transrepresses the hTERT promoter through an E-box located downstream of the hTERT transcription initiation site
In order to delineate which elements within the hTERT promoter are required for Tax effect, we generated several hTERT promoter-luciferase constructs carrying mutations in different responsive elements (Figure 3 ). Mutations were introduced in the two E-boxes, the DNA motifs known to be involved in Tax-associated transrepression, and in a motif that overlaps the 3 0 Ebox, the MT-box, a novel transcription-factor binding site involved in the regulation of hTERT transcription during cell differentiation (Tzukerman et al., 2000) . The negative effect of Tax on hTERT transcription observed with wild-type hTERT promoter (Figure 3 , lane 1) was completely abrogated when HeLa cells were cotransfected with pCMV-Tax and an hTERT construct having a mutation within the second E-box, located between positions 21 and 26 downstream of the hTERT transcription initiation site ( Figure 3, lanes 2, 3, 6, 7) . By contrast, mutations introduced in the first E-box, located between positions 182 and 187 upstream of the hTERT transcription initiation site, or in the MT motif, did not significantly alter the repression of hTERT by Tax (Figure 3 , lanes 4 and 5). 
Downregulation of telomerase activity in fresh lymphocytes transduced with a lentiviral vector expressing Tax
Having characterized the effect of Tax on hTERT transcription and telomerase activity in cell lines, we subsequently analysed telomerase activity in fresh, Taxexpressing PBMCs, the natural host cells for HTLV-1 infection in vivo (Nagai et al., 2001) . Hence, fresh CD4 þ and CD8 þ T cells, separated from the PBL of a healthy HTLV-1 seronegative blood donor, were transduced with a Tax recombinant nonreplicative HIV-1 vector containing the central DNA flap sequence (Zennou et al., 2000) . At 48 h from transduction and PHA stimulation, Tax-transduced cells and control cells transduced with a GFP recombinant HIV-1 vector were tested for telomerase activity. A strong inhibition of telomerase activity characterized Taxtransduced cells, when compared to control cells ( Figure 5 ).
Discussion
Present results are the first evidence of hTERT repression by a viral oncoprotein, thus displaying a molecular basis for hTERT inhibition at the premalignant stage of human cancers. Since hTERT is physiologically expressed by T-cell activation (Liu et al., 1999) , the effects of Tax on T cells may appear paradoxical: on the one hand Tax triggers T-cell activation (Hollsberg, 1999) and proliferation (Mortreux et al., 2001 (Mortreux et al., , 2003 Yoshida, 2001) , while on the other hand it blocks hTERT expression and thereby telomerase activity (present results). Theoretically, these two signals considered as contradictory for a T cell are synergic for triggering telomere attrition, thereby driving the cell towards apoptosis or permanent growth arrest through the p53 checkpoint (Saretzki et al., 1999) . However, nontransformed HTLV-1-infected T cells undergo Tax-mediated p53 inhibition (Uittenbogaard et al., 1995; PiseMasison et al., 1998; Pise-Masison et al., 2000; Yoshida, 2001 ) that mainly results from a competition between Tax and p53 for CBP/P300 binding (Pise-Masison et al., 2000) . In addition, although harboring a significant decrease of Tax expression, ATLL cells regularly remain deficient for p53 function. Hence, mutations of p53 are found in 20-40% of ATLL (Nagai et al., 1991; Cesarman et al., 1992; Sakashita et al., 1992; Nishimura et al., 1995) . Even in the absence of p53 mutations, HTLV-1-transformed lymphocytes are characterized by p53 inactivation (Reid et al., 1993; Takemoto et al., 2000) . Together with the present results, these data make it possible to propose that by inhibiting both p53 and hTERT in persistently proliferating cells (Cavrois et al., 1998) , Tax fosters persistent telomere dysfunction, thereby allowing accumulation of increased unbalanced chromosomal rearrangements (Blasco et al., 1997; Rudolph et al., 2001) which, if coupled with accumulating somatic mutations (Mortreux et al., 2001) , help move the cell towards the malignant genotype. Additional events, including accumulating stochastic mutations (Mortreux et al., 2001) , persistent p53 inactivation and decreased Tax expression (Furukawa et al., 1995; Hanon et al., 2000) , are thought to allow telomerase reactivation (Uchida et al., 1999) , thus endowing infected cells with immortal growth potential, stabilizing the genome and finally leading to ATLL. In contrast to Tax, other viral oncoproteins such as the E6 product of the human papilloma virus (HPV) type 16 (Klingelhutz et al., 1996) and the latencyassociated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpes virus (Knight et al., 2001) have been found to transactivate hTERT expression. In fact, these differences are consistent with and highlight the distinct oncogenic strategies used by these viruses. While E6 and LANA, both from DNA viruses, are continuously expressed in tumor cells (Klingelhutz et al., 1996; Knight et al., 2001) , Tax is only expressed during the premalignant phase of ATLL (Furukawa et al., 1995; Hanon et al., 2000) . Thus, via hTERT transactivation, LANA and E6 contribute to maintaining the malignant phenotype, whereas hTERT repression by Tax is restricted to early carcinogenesis.
Like ATLL, many cancers are preceded by a prolonged period of latency and display complex chromosomal abnormalities. We speculate that other carcinogens might play the same role as Tax and initiate malignant transformation by inactivating telomerase activity. Finally, dissecting the mechanisms by which Tax represses hTERT should help to better understand early carcinogenesis.
Methods
Plasmids pMT2Tmyc and pCMV-Tax plasmids were described previously (Smith and Greene, 1990; Wu et al., 1999) . hTERT luciferase reporter plasmids correspond to the wild-type hTERT promoter TERTLuc800 (Figure 3 , lane 1) and six additional plasmids carrying mutations. SM (lane 4) and DM (lane 2) were previously described (Wu et al., 1999) . M1-4 (lanes 3, 5-7) were generated by site-directed PCR mutagenesis.
Mutagenesis
M1-M4 plasmids were constructed using the QuickChange XL site-directed mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. Briefly, 10 ng plasmid template and 125 ng of each primer were incubated in a final volume of 50 ml. Each construct was sequenced to confirm incorporated mutations.
Cells, transfections and reporter assay
HeLa cells were transfected by the calcium phosphate precipitation method (Webster et al., 2000) , while Jurkat cells were transfected using Superfect (Qiagen, Courtaboeuf, France) according to the manufacturer's protocol. The total amount of transfected DNA and pCMV or pMT2T sequences were kept constant in each experiment. A plasmid expressing the secreted placental alkaline phosphatase (SEAP) was also transfected in each experiment to serve as an internal control for transfection efficiency. At 48 h after transfection, cells were collected and transcriptional activity was assayed as a function of luciferase activity (Nordeen, 1988) . Results were expressed as the induction of luciferase activity (Luciferase Assay System, Promega, Madison, WI, USA) of the hTERT promoter construct over pCMV and were normalized to SEAP activity (AP Chemiluminescent Reporter Gene Assay, ICN Pharmaceuticals, Costa Mesa, CA, USA). Data shown in 
Western blot
Cells were lysed and protein concentration was assayed using the Bio-rad D c Protein Assay Kit (Bio-rad, Hercules, CA, USA). Equal amounts of proteins were subjected to sodium dodecyl sulfate 8% polyacrylamide gel electrophoresis. Fractionated proteins were transferred to PVDF membranes (Immobilon-P Transfer Membranes, Millipore, Bedford, MA, USA). Membranes were blocked in PBS containing 5% nonfat milk, 0.2% Tween 20, then probed with the appropriate antibody: Tax monoclonal antibody HY474, c-Myc monoclonal antibody Anti-myc (Invitrogen) and monoclonal antiactin (AC-40 or AC-15, Sigma, Saint Louis, MI, USA), followed with the anti-mouse IgG HRP-linked antibody (Cell Signaling Technology, Beverly, MA, USA). Blots were then 
Telomeric repeat amplification protocol (TRAP) assays
Cell lysate preparation (approximately 4 mg of protein per sample) and TRAP assay using 32 P-labelled primers (TRAP Assay, Pharmingen, San Diego, CA, USA) were carried out according to the manufacturer's protocol. Band quantitation was performed by laser densitometric scanning of X-ray films exposed in the linear range (Figure 1a ). For transfected HeLa cells (Figure 2d ), telomerase activity was quantified on cellular extracts (0.5 mg) by a TRAP-ELISA assay (Roche, Indianapolis, IN, USA), as described (Gauthier et al., 2001) . TRAP products were quantified by absorbency reading of the reaction mixtures at 450 nm. Results were expressed as the induction of cellular telomerase activity and were normalized to SEAP activity.
PCR
hTERT and Tax expressions were assayed by RT-PCR (Figure 2c ). Actin mRNA was amplified as control. RNA was extracted from transfected cells using the SV total RNA isolation System (Promega, Madison, WI, USA) according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized using the M-MLV Reverse Transcriptase (Invitrogen, Groningen, the Netherlands) and 75-150 ng cDNA was subjected to 30 cycles of PCR in a total volume of 50 ml. The following sequences of primers were used: forward primer: 5 0 -TGAACTTGCGGAAGACAGTG-3 0 (hTERT), 5 0 -CGGATACCCAGTCTACGTGT-3 0 (tax), 5 0 -GGCATGGTCACCAACTGGGACGAC-3 0 (actin), and reverse primer: 5 0 -ACATGCGTGAAACCTGTACG-3 0 (hTERT), 5 0 -GAGCCGATAACGCGTCCATCG-3 0 (tax), 5 0 -ATTTGCGGTGGACGATGGAGGGGC-3 0 (actin). Actin, Tax and hTERT RT-PCR products shown in Figure 2c are derived from the exponential phase of the amplification.
Retroviral transduction
Peripheral blood lymphocytes (PBLs) obtained from a healthy donor were stimulated with 1 mg/ml of phytohemagglutinin (Wellcome, Research Triangle Park, NC, USA), and then maintained in the presence of interleukin-2 (10% lymphocult; Biotest Diagnostics, Denville, NJ, USA). CD4 þ T cells or CD8 þ T cells were negatively selected from PBLs with magnetic beads (MACS CD41 or CD81 T-cell isolation kit; Miltenyi Biotech, Paris, France) according to the manufacturer's instructions. CD4
þ and CD8 þ T cells were transduced with a Tax recombinant nonreplicative HIV-1 vector or a GFP control vector, both carrying the central DNA flap sequence, as described (Zennou et al., 2000; Royer-Leveau et al., 2002) . Transductions were conducted at a vector particle concentration of 500 ng P24/ml. Transduction efficiencies were superior to 80% in all cases (not shown). Telomerase activity was measured at 48 h after stimulation with 1 mg/ml of phytohemagglutinin. Figure 5 Telomerase inactivation in fresh CD4 þ and CD8 þ T cells transduced with a Tax recombinant nonreplicative HIV-1 vector. Peripheral blood lymphocytes (PBLs) derived from a healthy donor were stimulated with phytohemagglutinin, and maintained in the presence of Interleukin-2. CD4 þ T cells or CD8 þ T cells were negatively selected from PBLs. CD4 þ T cells and CD8
þ T were transduced with a Tax recombinant nonreplicative HIV-1 vector or a GFP control vector, as detailed in the Methods section. At 48 h from transduction and PHA stimulation, cells were assayed for telomerase activity by TRAP-ELISA, as detailed in the Methods section
